Other

Lipocine Inc.

Joel Frank

Mahesh V Patel

Nachiappan Chidambaram

Srinivasan Venkateshwaran

Satish Kumar Nachaegari

Kilyoung Kim

Amy Jo Portlock

Described here are substantially pure (17-&#x3b2;)-3-Oxoandrost-4-en-17-yl tridecanoate compositions, methods of their preparation and uses thereof.

(17-&#xdf;)-3-oxoandrost-4-en-17YL tridecanoate compositions and methods of their preparation and use

Disclosed are bioavailable solid state (17-&#x3b2;)-3-Oxoandrost-4-en-17-yl dodecanoate compositions and methods of use in administration to mammals in need of thereof. The (17-&#x3b2;)-3-Oxoandrost-4-en-17-yl dodecanoate is preferably provided in a solid state crystalline form having a plurality of peaks corresponding to the peaks shown in FIG., a plurality of crystallites ranging in size from about 40 nm to about 60 nm based as identified via powder x-ray diffraction spectra, and a melting point in the range of about 51&#xb0; C. to about 63&#xb0; C. The compositions may be provided in oral or injectable administration form for the treatment of conditions such as in need of testosterone therapy. An exemplary chemical structure of a (17-&#x3b2;)-3-Oxoandrost-4-en-17-yl dodecanoate composition disclosed herein is as follows: 

(17-)-3-oxoandrost-4-en-17-yl dodecanoate compositions and methods of preparation and use

Disclosed are bioavailable solid state (17-&#x3b2;)-Hydroxy-4-Androsten-3-one esters suitable for pharmaceutical uses and administration to mammals in need of (17-&#x3b2;)-Hydroxy-4-Androsten-3-one.

Bioavailable solid state (17-&#x3b2;)-hydroxy-4-androsten-3-one esters

Growing community of inventors

Sandy, UT, United States of America

Joel Frank